Barber M, Boloix A, Parrilla A, Köber K, Avilés-Domínguez L, Ventosa N, Ramírez-Morales LC, Perez-Benavente A, Gil-Moreno A, Colàs E, Morote J, Segura MF, Méndez O, Santamaria A.
BORA overexpression promotes epithelial-mesenchymal transition and metastasis in ovarian cancer: Unveiling a novel therapeutic target for advanced disease.
Clinical and Traslacional Medicine. 2025 Apr;15(4):e70285.
DOI: 10.1002/ctm2.70285
IF: 6.8
RESEARCH GROUPS
Biomedical research in Urology
11
Number of publications
72.73
%
% Q1
27.27
%
% D1
81.82
%
% Leadership
44.44
%
% Female Leadership
1.38
CROWN (2021-2025)
14.04
%
HCP10% (2021-2025)
90.91
%
% Open access
36.36
%
% International Collaboration
1
Highly cited papers / HCP 1% (2021-2025)
1
Publications in high-IF journals with high Altmetric scores
5
Number of Ongoing Projectes (total)
1
International ongoing projects
0
Number of New projects (total)
0
International new projects
11
Number of Active clinical Trials
2
Number of New Clinical Trials
1
Number of Theses
The Biomedical Research in Urology team has built a strong translational oncology program integrating molecular biology, biomarker discovery, advanced imaging, predictive modeling, and clinical implementation, focused on prostate, kidney, and bladder cancer. Their work includes mechanistic studies to identify therapeutic targets, high-throughput proteomics, and relevant preclinical models. A key priority is improving early detection and risk stratification in prostate cancer using MRI-based risk calculators, biomarker integration, optimized biopsy strategies, and structured diagnostic pathways. The team also assesses AI and machine learning tools to ensure clinical utility and interpretability. By combining laboratory research with prospective clinical studies and interdisciplinary collaboration, they advance precision oncology through practical diagnostic and prognostic tools that improve outcomes and quality of life.
CORE/MISSIONS
- AI, Data, Imaging & Digital Health
- Innovative & Advanced Therapies
- Transplant & Immunomodulation
PROGRAMS
TEAM
Group Leader
Enrique Trilla Herrera
Principal Investigator (PI)
Enrique Trilla Herrera / Olga Méndez
Researchers
Olga Méndez, Jacques Planas, Mercè Cuadras, Ana Celma, Lucas Regis, Inés de Torres, Maria Eugenia Semidey, David Lorente, Carles Xavier Raventés, Fernando Lozano, Albert Carrión, Miriam Campistol, Ana Sarrias
PhD Students
Lidia Ramírez
Lab Technicians
Maria Granda
SELECTED PUBLICATIONS
Morote J, Miró B, Hernando P, Paesano N, Picola N, Muñoz-Rodriguez J, Ruiz-Plazas X, Muñoz-Rivero MV, Celma A, García-de Manuel G, Servian P, Abascal JM, Trilla E, Méndez O.
Developing a Predictive Model for Significant Prostate Cancer Detection in Prostatic Biopsies from Seven Clinical Variables: Is Machine Learning Superior to Logistic Regression?.
Cancers (Basel). 2025 Mar 25;17(7):1101.
DOI: 10.3390/cancers17071101
IF: 4.4
Campistol M, Lozano F, Carrion A, Raventós CX, Morote J, Trilla E.
Active Surveillance in Non-Muscle Invasive Bladder Cancer: A Systematic Review.
Cancers (Basel). 2025 May 20;17(10):1714.
DOI: 10.3390/cancers17101714
IF: 4.4
Paesano N, Catalá V, Tcholakian L, Alomar X, Barranco MÁ, Hernández-Mancera J, Miró B, Trilla E, Morote J.
Validation of the Barcelona Magnetic Resonance Imaging Predictive Model for Significant Prostate Cancer Detection in Men Undergoing Mapping per 0.5 Mm-Core Targeted Biopsies of Suspicious Lesions and Perilesional Areas.
Cancers (Basel). 2025 Jan 31;17(3):473
DOI: 10.3390/cancers17030473.
IF: 4.4
Paesano N, Picola N, Muñoz-Rodriguez J, Ruiz-Plazas X, Muñoz-Rivero MV, Celma A, García-de Manuel G, Miró B, Servian P, Abascal JM, Trilla E, Morote J.
Efficacy of Prostate Biopsies via Transperineal and Transrectal Routes for Significant Prostate Cancer Detection: A Multicenter Paired-Matched Study.
Diagnostics (Basel). 2025 Jan 26;15(3):288
DOI: 10.3390/diagnostics15030288
IF: 3.3
SELECTED PROJECTS
Nuevas estrategias para la mejora del diagnóstico y el manejo terapéutico de los portadores de mutaciones en BRCA2 (PI21/00977).
Principal Investigator: Anna Santamaria Margalef
Agency: Instituto de Salud Carlos III
Funding: 159,720 €
Period: 2022-2024. Extended until June 2026.
FLUTE: Federated Learning and mUlti-party computation Techniques for prostatE cancer. HORIZON-HLTH-2022-IND-13-02 topic.
Principal Investigator: Olga Méndez/ Enrique Trilla
Agency: European Union.
Funding: 490,375€
Period: 2023-2025
Incorporación de nuevos métodos de imagen y perfiles moleculares para mejorar el cribado de cáncer de próstata en portadores de mutaciones en genes de las vías de reparación de ADN (PI23/01310).
Principal Investigator: Olga Méndez
Agency: Instituto de Salud Carlos III
Funding: 127,500€
Period: 2024-2026
KidneyColor: machine learning sobre fotografía digital macroscópica para la predicción de la funcionalidad del trasplante renal de cadáver.
Principal Investigator: Enrique Trilla
Agency: Asociación Española de Urología
Funding: 25,000€
Period: 2023-2025
Desarrollo y validación de un algoritmo de predicción de la disfunción primaria del trasplante renal mediante el uso de inteligencia artificial y procesamiento de imágenes (Kidney Color) (PI24/00895).
Principal Investigator: Enric Miret Alomar / Enric Trilla Herrera
Agency: Instituto de Salud Carlos III
Funding: 52,500€
Period: 2025-2027
PATENTS
INHIBITOR OF MAP KINASE INTERACTING SERINE/THREONINE KINASE 1 (MNK1) AND MAP KINASE INTERACTING SERINE/THREONINE KINASE 2 (MNK2), CANCER THERAPY METHODS AND THERAPEUTIC COMBINATIONS
Priority Number: PCT/EP2020/069459 (WO2021005183)
Priority Date: 09/07/2020
Applicants: Ramon y Cajal, Santiago; Hümmer, Stefan; Castellvi, Josep; Martinez Sáez, Elena; Borrell, José; Teixidó, Jordi; Estrada, Roger; Bou Petit, Elisabeth; Peg, Vicente; Guijarro, Pedro; Santamaria, Anna; Morote, Joan; Suarez, Leticia.
Development of an Automated System for Continuous Vesical Irrigation (Vesiclean)
Priority Number: 0
Priority Date: 0
Applicants: Dr. Lorente is leading the development of an automated system for continuous vesical irrigation (Vesiclean), in collaboration with Montse Llinàs at the Vall d’Hebron Research Institute and the company Vecmedical. A first proof-of-concept clinical study was successfully conducted in 2024, and the team is currently advancing the development and validation of the final device model in preparation for broader clinical implementation.
DISSEMINATION ACTIVITIES
Participation in activities organized by the Movember Foundation
Place: Barcelona
Date: 01/11/2025
Brief: In collaboration with other researchers and clinicians on our campus.
International Day of Women and Girls in Science
Place: Barcelona
Date: 11/02/2025
Brief: Participation in the activities organized by VHIR for the International Day of Women and Girls in Science (February 11), including visits by school students to our laboratory.
